3164 — Genmont Biotech Cashflow Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesBalancedMicro CapFalling Star

Annual cashflow statement for Genmont Biotech, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	76.8	139	66.3	28.2	64.7
Depreciation
Amortisation
Non-Cash Items	1.64	-14.7	4.66	-17.8	-13
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	18.9	-34.2	16.6	-40.6	0.616
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	118	112	138	34.6	124
Capital Expenditures	-139	-117	-71.2	-35.5	-44.3
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	146	-36	-12.5	-39.8	-38.1
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	6.78	-153	-83.7	-75.4	-82.4
Financing Cash Flow Items	86.2	0	5.35	0	-0.05
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-49.3	-61.4	-91.1	-36.8	12.6
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	83.2	-105	-36.3	-78.1	54.9